Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy‐resistant preleukemic clones
Open Access
- 7 January 2021
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 148 (11) , 2825-2838
Abstract
To acquire a better understanding of clonal evolution of acute myeloid leukemia (AML) and to identify the clone(s) responsible for disease recurrence, we have comparatively studied leukemia‐specific mutations by whole‐exome‐sequencing (WES) of both the leukemia and the nonleukemia compartments derived from the bone marrow of AML patients. The T‐lymphocytes, B‐lymphocytes and the functionally normal hematopoietic stem cells (HSC), that is, CD34+/CD38−/ALDH+ cells for AML with rare‐ALDH+ blasts (+ cells) were defined as the nonleukemia compartments. WES identified 62 point‐mutations in the leukemia compartment derived from 12 AML‐patients at the time of diagnosis and 73 mutations in 3 matched relapse cases. Most patients (8/12) showed 4 to 6 point‐mutations per sample at diagnosis. Other than the mutations in the recurrently mutated genes such as DNMT3A, NRAS and KIT, we were able to identify novel point‐mutations that have not yet been described in AML. Some leukemia‐specific mutations and cytogenetic abnormalities including DNMT3A(R882H), EZH2(I146T) and inversion(16) were also detectable in the respective T‐lymphocytes, B‐lymphocytes and HSC in 5/12 patients, suggesting that preleukemia HSC might represent the source of leukemogenesis for these cases. The leukemic evolution was reconstructed for five cases with detectable preleukemia clones, which were tracked in follow‐up and relapse samples. Four of the five patients with detectable preleukemic mutations developed relapse. The presence of leukemia‐specific mutations in these nonleukemia compartments, especially after chemotherapy or after allogeneic stem cell transplantation, is highly relevant, as these could be responsible for relapse. This discovery may facilitate the identification of novel targets for long‐term cure.Keywords
Funding Information
- Deutsche Forschungsgemeinschaft (SFB 873)
- Dietmar Hopp Stiftung
This publication has 32 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid LeukemiaScience Translational Medicine, 2012
- Identifying leukemia stem cells – Is it feasible and does it matter?Cancer Letters, 2012
- The role of mutations in epigenetic regulators in myeloid malignanciesNature Reviews Cancer, 2012
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- A clinically relevant population of leukemic CD34+CD38− cells in acute myeloid leukemiaBlood, 2012
- Current findings for recurring mutations in acute myeloid leukemiaJournal of Hematology & Oncology, 2011
- Mutational Inactivation of STAG2 Causes Aneuploidy in Human CancerScience, 2011
- Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML IntergroupBlood, 2003
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002